Journal: Journal of the Endocrine Society

Article Title: Continuous Glucose Monitoring in Patients With Postbariatric Hypoglycemia: Effect on Hypoglycemia and Quality of Life

doi: 10.1210/jendso/bvaf106

Figure Lengend Snippet: Study design overview. Participants were first screened, randomized, and trained in CGM use. Subjects were then assigned to begin with either a 10-day unblinded CGM (Dexcom G6) or 10-day blinded CGM (Dexcom G6 Pro) period. Each monitoring phase was followed by completion of the Hypoglycemia Fear Survey-II (HFS-II), an event diary, and training (if applicable) with a new CGM device. All participants crossed over to the alternate CGM modality for another 10-day period. The study concluded with repeated HFS-II assessments, event diary entries, and CGM data download. Blinded CGM data (Dexcom G6 Pro) was used for all outcome analyses to ensure consistency.

Article Snippet: Patients with confirmed PBH were screened for eligibility and if enrolled, were assigned to 2 treatment periods given sequentially but in random order to avoid confounding by treatment order: (1) a 10-day period with use of unblinded Dexcom G6 (the intervention of interest) and (2) a 10-day control period without use of unblinded Dexcom G6 ( ).

Techniques:

Journal: AACE Endocrinology and Diabetes

Article Title: Glucagon-Like Peptide 1 Agonist Use in an Adult With Cystic Fibrosis–Related Diabetes and Metabolic Syndrome

doi: 10.1016/j.aed.2025.03.011

Figure Lengend Snippet: Changes in continuous glucose monitor measure before and 6 months after semaglutide initiation. A , Before semaglutide initiation. B , Six months after semaglutide initiation. The figure depicts Dexcom G7 CGM Clarity data from 2 14-day periods. A , Glycemic data from the 2 weeks prior to initiation of semaglutide. B , Glycemic data from 6 months after initiation at a dosage of 2.0 mg weekly.

Article Snippet: The figure depicts Dexcom G7 CGM Clarity data from 2 14-day periods.

Techniques: